Connect with us

Hi, what are you looking for?

press release

CNRS and Astrid Research to Conduct Joint Research on Melanoma Therapy

Centre National de la Recherche Scientifique, the National Center for Scientific Research of France and Astrid Research Inc, a Hungary-based bioinformatics company, today announced that they started a collaboration on a basic research project aimed at the development of a nucleic acid based melanoma therapy.

Orleans, France and Debrecen, Hungary – November 30, 2010 – Centre National de la Recherche Scientifique, the National Center for Scientific Research of France and Astrid Research Inc, a Hungary-based bioinformatics company, today announced that they started a collaboration on a basic research project aimed at the development of a nucleic acid based melanoma therapy.

Nucleic acids play a dominant role in coordinating and maintaining cell functions. Therapeutic developments targeting impaired cells at the nucleic acid level is currently considered as innovative and promising approach in nanomedicine. Melanoma is an aggressive malignancy with a continuously increasing incidence – and unfortunately with limited therapeutic potentials.

“The most important technological challenges that need to be addressed in order to realize the promise of nucleic acid-based approaches to treating melanoma are efficient and safe delivery of the compounds to the targeted organs, and uptake of these compounds by relevant cells.” said Chantal Pichon PhD, Professor of Molecular and Cell Biology at University of Orléans.

The research team led by Pr. Pichon at Centre de Biophysique Moléculaire (Molecular Biophysics institute) located at the CNRS campus of Orléans pursues extensive research on non-viral gene transfer methods and investigation of different routes for delivery into the cells. With the computational prediction possibilities provided by Astrid Research the joint team can successfully complete the drug candidate development process.

“High-throughput technologies created a huge demand for computational extensive bioinformatics applications – a specialty of our company. Our tools for in-silico design and modeling can support researches from the very beginning of the projects.” said Dr. Zsolt Torok, Chief Scientific Officer at Astrid Research Inc.
Preliminary results are convincing: upon administration of the compound, a longer survival period and a better progression rate was observed in mice. After modifications identified and carried out through the collaborative work, enhanced efficiency is hoped to be attained. Later on a clinical trial might be initiated.

About CNRS
The Centre National de la Recherche Scientifique (National Center for Scientific Research) is a government-funded research organization, under the administrative authority of France’s Ministry of Research. As the largest fundamental research organization in Europe, CNRS carried out research in all fields of knowledge. For more information visit: http://www.cnrs.fr/index.php

About Astrid Research Inc.
Headquartered in Debrecen, Hungary, Astrid Research is one of the largest bioinformatics companies in Central and Eastern Europe. Astrid conducts extensive research and development activities to create software solutions for research institutions, university labs, pharmaceutical and biotech companies that are involved in preclinical genomic research. For more information visit: http://www.astrid.hu

Media Contact:
Zoltan Kovacs
+36209509835
zoltan.kovacs@astrid.hu
http://www.astrid.hu

Press release courtesy of Online PR Media: http://bit.ly/fodwNa

You May Also Like

Business

State would join dozens of others in enacting legislation based on federal government’s landmark whistleblower statute, the False Claims Act

press release

With a deep understanding of the latest tech, Erbo helps businesses flourish in a digital world.

press release

#Automotive #Carbon #Canister #Market #Projected #Hit #USD New York, US, Oct. 24, 2022 (GLOBE NEWSWIRE) —  According to a comprehensive research report by Market...

press release

Barrington Research Analyst James C.Goss reiterated an Outperform rating on shares of IMAX Corp IMAX with a Price target of $20. As theaters...